ArticleScientific reports2016
MicroRNA-126 contributes to Niaspan treatment induced vascular restoration after diabetic retinopathy.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Association of alcohol intake with risk of diabetic retinopathy: a meta-analysis of observational studies.Scientific reports · 2017Pooled it
- The Amelioration of Detrimental Biochemical Anomalies by Supplementing B, C, and E Vitamins in Subjects with Type 2 Diabetes Mellitus May Reduce the Rate of Development of Diabetic Retinopathy.Journal of diabetes research · 2022Trial
- Dysfunction of the Neurovascular Unit in Diabetic Retinopathy: Advances from Molecular Mechanisms to Targeted Interventions.Stem cell reviews and reports · 2026Review
- MicroRNAs: A Social Network in Diabetic Retinopathy.Biomolecules · 2026Review
- Diabetic Retinopathy and Current Treatment Approaches: From Pathogenesis to Extracellular Vesicle-Based Therapies.International journal of molecular sciences · 2026Review
- MicroRNA Profiles Targeting Angiopoietin-1, Angiopoietin-2, and TEK Receptor Tyrosine Kinase-2 Genes Associated with Angiogenesis in Proliferative Diabetic Retinopathy.Turkish journal of ophthalmology · 2026Article
- Exploring the role of miR-126 in diabetes and its complications: a comprehensive review.Diabetology & metabolic syndrome · 2025Review
- Review
- Association between dietary niacin intake and diabetic retinopathy in a Catalonian population: a cross-sectional study.Frontiers in nutrition · 2025Article
- Large-Scale Isolation of Milk Exosomes for Skincare.Pharmaceutics · 2024Article
- Role of MicroRNA in linking diabetic retinal neurodegeneration and vascular degeneration.Frontiers in endocrinology · 2024Review
- Long Non-Coding RNAs and Proliferative Retinal Diseases.Pharmaceutics · 2023Review
- Exosomes as biomarkers and therapy in type 2 diabetes mellitus and associated complications.Frontiers in physiology · 2023Review
- Noncoding RNAs Are Promising Therapeutic Targets for Diabetic Retinopathy: An Updated Review (2017-2022).Biomolecules · 2022Review
- Relationship of miRNA‑126 and miRNA‑122 expression with type 2 diabetes mellitus and related glucose metabolism parameters: A systematic review and meta‑analysis.Experimental and therapeutic medicine · 2022Article
- MicroRNAs may provide new strategies in the treatment and diagnosis of diabetic retinopathy: Importance of VEGF.Iranian journal of basic medical sciences · 2021Review
- Antioxidants for the Treatment of Retinal Disease: Summary of Recent Evidence.Clinical ophthalmology (Auckland, N.Z.) · 2021Review
- MicroRNAs in Vascular Eye Diseases.International journal of molecular sciences · 2020Review
- MicroRNA and Microvascular Complications of Diabetes.International journal of endocrinology · 2018Review
- miR-15a/16 inhibits TGF-beta3/VEGF signaling and increases retinal endothelial cell barrier proteins.Vision research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic retinopathy (DR) is a serious microvascular complication of diabetes and a major cause of blindness in the developing world. Early diabetic retinopathy is characterized by a loss of pericytes and vascular endothelial cells, a breakdown of the blood-retinal barrier, vascular dysfunction and vascular-neuroinflammation. However, optimal treatment options and related mechanisms are still unclear. MicroRNA-126 (miR-126) plays a potential role in the pathogenesis in DR, which may regulate VEGF, Ang-1 and VCAM-1 expressions. This study investigated the therapeutic effects and mechanisms of Niaspan treatment of DR in diabetes (DM) rats. DM rats exhibits significantly decreased miR-126 and tight junction Claudin-5/Occludin/ZO-1 genes expression, and increased Blood retinal-barrier (BRB) breakdown, retinal apoptosis and VEGF/VEGFR, as well as VCAM-1/CD45 expressions in the retina compared to normal control group. Niaspan treatment significantly improved clinical and histopathological outcomes; decreased the expressions of VEGF/VEGFR, VCAM-1/CD45, apoptosis and BRB breakdown, significantly increased tight junction proteins and Ang-1/Tie-2 expressions, as well as increased retinal miR-126 expression compared to non-treatment diabetic rats. These data are the first to show that Niaspan treatment ameliorates DR through its repair vascular and inhibits inflammatory effects, and also suggest that the miR-126 pathway may contribute to Niaspan treatment induced benefit effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.